Cosmos Health Targets $200M Revenue, $44M EBITDA by 2029, Projects Profitability by 2027
COSM is trading near its 52-week low of $0.246 (6.3% above the low).
Summary
Cosmos Health announced ambitious 2026-2029 financial guidance, targeting $200 million in revenue and $44 million in adjusted EBITDA by 2029. The company also projects achieving profitability by 2027, with net income reaching $31 million and $0.73 EPS by 2029. This highly optimistic outlook directly contrasts with recent SEC filings, including the 10-K and 10-Q, which reported going concern warnings, significantly widened losses, and increased cash burn. The projected growth and path to profitability are substantial for a company of its current size, potentially alleviating investor concerns about its financial viability.
At the time of this announcement, COSM was trading at $0.26 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $14.3M. The 52-week trading range was $0.25 to $1.32. This news item was assessed with positive market sentiment and an importance score of 9 out of 10. Source: Reuters.